CBER Maintains Framework for Three Allergenic Products

Potency standardization remains the sharpest compliance variable for manufacturers working within CBER's allergenic biologics portfolio, where the distinction between standardized and non-standardized injectable extracts carries direct consequences for lot-release testing and labeling obligations. The Center for Biologics Evaluation and Research currently licenses three product categories: allergen extracts, allergen patch tests, and antigen skin tests.

Injectable allergen extracts form the largest subset. Manufactured from natural substances including molds, pollens, insect venoms, and animal hair, these sterile liquids are used for both diagnosis and treatment of conditions such as allergic rhinitis, allergic conjunctivitis, and bee venom allergy. Injectable extracts indicated for food allergies are restricted to diagnostic use only. For standardized extracts, a validated potency method applies on a lot-by-lot basis; non-standardized extracts carry no equivalent potency measure, a gap that has drawn sustained regulatory scrutiny, including a Federal Register notice extending the comment period on CBER's review of scientific and medical literature on non-standardized products.

Sublingual allergen extract tablets occupy a narrower regulatory lane: treatment use only, indicated for allergic rhinitis with or without allergic conjunctivitis, and similarly derived from natural allergenic substances. Contract manufacturers and QA teams handling either format should note that the two delivery forms sit under distinct labeling and sterility requirements, with injectable products subject to 21 CFR Part 610 general biologics standards alongside product-specific licensing conditions.

The two diagnostic categories round out CBER's allergenic scope. Allergen patch tests, applied to the skin surface to identify contact dermatitis triggers such as nickel, rubber, and fragrance mixes, are manufactured from both natural substances and chemicals. Antigen skin tests, injected intradermally, support diagnosis of infection with specific pathogens rather than allergic disease. Oral immunotherapy, in which a food-allergic individual consumes incrementally increasing allergen doses to reduce reaction risk, is also addressed within CBER's allergenic framework, though it represents a distinct clinical and manufacturing profile from extract-based products.

For QA directors and regulatory affairs leads, the non-standardized extract dossier warrants ongoing attention: CBER's 2011 Federal Register notice and the still-open literature review signal that the agency's position on potency requirements for this subset has not reached a final rulemaking stage, leaving manufacturers to operate under existing licensing conditions while the evidentiary record develops.

The Allergenic Products Advisory Committee and published allergenics guidances remain the primary reference points as CBER's lot-release and potency standardization expectations continue to evolve for this category.

Source: FDA Center for Biologics Evaluation and Research (CBER) via FDA.gov, September 3, 2026.